Replies to post #170903 on Biotech Values

[ghmm]

Clinical Impact of Ponatinib Dose Modification in Patients with Philadelphia Chromosome–Positive Leukemias

A 15 mg reduction in average daily dose intensity is predicted to lead to ~40%
reduction in the risk of arterial thrombotic events

http://congressposters.ariad.com/downloads/packages/37/ASH2013_PACE_DoseMod_poster_FINAL.pdf

Thanks to @chasingthealpha